Sysmex CA-500 - 600 Series System Reference Guide 3.05
Sysmex CA-500 - 600 Series System Reference Guide 3.05
Sysmex CA-500 - 600 Series System Reference Guide 3.05
Trademarks
Actin, BCT, Berichrom, Ci-Trol, Dade, Data-Fi, INNOVANCE, Innovin, Multifibren, Pathromtin and
Thromborel are trademarks of Siemens Healthcare Diagnostics.
SYSMEX is a trademark of SYSMEX CORPORATION.
Note
Siemens Healthcare Diagnostics has validated the provided instructions, reagents, instruments, software and
customizable features for this system to optimize product performance and meet product specifications. User
defined modifications are not supported by Siemens as they may affect performance of the system and test
results. It is the responsibility of the user to validate any modifications made to these instructions, instruments,
reagents or software provided by Siemens.
Emil-von-Behring-Str. 76
35041 Marburg
Germany
Revision History
Document Date Changes
Reference Guide 2014-12 New Application Sheets
3.05 None
Newly symbols for the reagents and controls (in accordance with IFU) used.
Changes in detail
None
Previous Reference - See respective Reference Guide
Guide Versions
Table of Contents
Normal printed version number: Current version of the Application Sheet, no changes to the previous
Reference Guide
Bold version number: New Application Sheet version in this Reference Guide
® ®
11 PT INR calibrated with Dade Innovin ................................................................................................................34
15 Derived Fibrinogen with Dade® Innovin® ..............................................................................................................38
APTT
13 APTT with Dade® Actin® Activated Cephaloplastin Reagent ................................................................................41
® ®
13 APTT with Dade Actin FS Activated PTT Reagent ...........................................................................................44
13 APTT with Dade® Actin® FSL Activated PTT Reagent .........................................................................................47
®
13 APTT with Pathromtin SL ...................................................................................................................................50
Fibrinogen
®
14 Fibrinogen with Multifibren U ..............................................................................................................................53
15 Fibrinogen with Dade® Thrombin Reagent ...........................................................................................................56
Clotting Assays
®
10 Coagulation Factor VII with Thromborel S ..........................................................................................................70
11 Coagulation Factor VII with Dade® Innovin® .........................................................................................................73
® ®
11 Coagulation Factor VIII with Dade Actin Activated Cephaloplastin Reagent.....................................................76
11 Coagulation Factor VIII with Dade Actin® FSL Activated PTT Reagent ..............................................................80
®
®
12 Coagulation Factor VIII with Pathromtin SL ........................................................................................................84
11 Lupus Anticoagulant with LA 1 Screening Reagent / LA 2 Confirmation Reagent................................................88
14 Protein C with Protein C Reagent ........................................................................................................................92
Chromogenic Assays
®
06 Antithrombin with INNOVANCE Antithrombin .....................................................................................................95
®
13 Antithrombin III with Berichrom Antithrombin III (A) ............................................................................................98
®
12 Heparin with Berichrom Heparin .......................................................................................................................101
06 Heparin (LMW) with Berichrom® Heparin ...........................................................................................................104
®
06 Heparin (UF) with Berichrom Heparin...............................................................................................................107
®
13 Protein C with Berichrom Protein C ..................................................................................................................110
Immunoassays
13 D-Dimer with D-Dimer PLUS ..............................................................................................................................113
13 D-Dimer with Advanced D-Dimer .......................................................................................................................117
10 D-Dimer with INNOVANCE® D-Dimer ................................................................................................................121
11 von Willebrand Factor with vWF Ag ...................................................................................................................126
Others
®
04 von Willebrand Factor with INNOVANCE VWF Ac ...........................................................................................131
Appendix I
Information on CA CLEAN I, CA CLEAN II and Dade® CA System Buffer .........................................................136
Appendix II
Symbol names of required Materials ..................................................................................................................137
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
® ®
Dade Ci-Trol 3 291072 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I Rinse position 11
964-0631-3 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 378
Hemoglobin mg/dL 1000
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Thromborel® S on Sysmex® CA-6000 System y = 1.00 x - 0.50 0.999
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 1,1 1,0 1,5
CONTROL N 0.7 0.7 0.9
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Median 2.5 - 97.5 Percentile
— 158 10.2 9.3 - 11.6
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 180 sec
Reag. Vol PT THS 100 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
PT-Multi CALIBRATOR Sample rack OPAT
position 1 - 5 6 x 1 mL Sample rack position 1 - 5
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
®
PT-Multi Calibrator Level 6 is not used in combination with Thromborel S.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 378
Hemoglobin mg/dL 1000
Bilirubin mg/dL 6
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Calibration with FNP pool using Thromborel® S on Sysmex® CA-500 series System y = 1.02 x + 0.54 0.999
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 2/ Dade® Ci-Trol® 2 2.6 2.7 3.7
CONTROL N 2.2 1.7 2.6
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: % of norm
th th
Comments n Median 2.5 - 97.5 Percentile
— 158 102 79 - 122
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
If the Derived Fibrinogen method is also used on the instrument, the Derived Fibrinogen method has to be disabled during the calibration
with PT-Multi Calibrator to avoid overwriting the Derived Fibrinogen master curve.
- Press [Standard Curve] - [Select Param.], disable the parameter No. 4 “dFbg”
- Perform calibration with PT-Multi Calibrator according to the Application Sheet
- Press [Standard Curve] - [Select Param.], enable the parameter No. 4 “dFbg”
Nevertheless, please check all calibration curve data afterwards.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
STANDARD PLASMA [2] Sample rack ORKL
position 1 1 mL Sample rack position 1
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
® ®
Dade Ci-Trol 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
® ®
Dade Ci-Trol 3 291072 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I Rinse position 11
964-0631-3 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Optional; only required to establish the MNPT.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 450
Hemoglobin mg/dL 600
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Thromborel® S on Sysmex® CA-6000 System y = 0.89 x + 0.11 0.999
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 1.0 0.9 1.3
CONTROL N 0.6 0.6 0.8
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
System specific MNPT and ISI have to be used.
The Mean Normal PT (MNPT) can be established with Standard Human Plasma. To use Standard Human Plasma, it has to be measured at
least twice and the obtained clotting time has to be divided by the ratio given for the PT reagent in the lot-specific Table of Analytical Values
of the plasma.
ISI values for prothrombin time must be entered directly as they appear on the lot-specific table of ISI values. Any changes of the reagent lot,
software (upgrades), major service, etc., require verification of the ISI value. Failure to enter the correct ISI value will cause incorrect
International Normalization Ratio (INR) results.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
PT-Multi CALIBRATOR Sample rack OPAT
position 1 - 5 6 x 1 mL Sample rack position 1 - 5
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
®
PT-Multi Calibrator Level 6 is not used in combination with Thromborel S.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 378
Hemoglobin mg/dL 1000
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Calibration with MNPT and ISI using Thromborel® S on Sysmex® CA-500 series System y = 0.85 x + 0.16 1.000
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 1.4 1.9 2.3
CONTROL N 0.9 1.1 1.4
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
If the Derived Fibrinogen method is also used on the instrument, the Derived Fibrinogen method has to be disabled during the calibration
with PT-Multi Calibrator to avoid overwriting the Derived Fibrinogen master curve.
- Press [Standard Curve] - [Select Param.], disable the parameter No. 4 “dFbg”
- Perform calibration with PT-Multi Calibrator according to the Application Sheet
- Press [Standard Curve] - [Select Param.], enable the parameter No. 4 “dFbg”
Nevertheless, please check all calibration curve data afterwards.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
Ci-Trol CONTROL 2 B4244-20 1 mL Any position on sample rack
® ®
Dade Ci-Trol 2 291071 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL ---*
Hemoglobin mg/dL 100
Bilirubin mg/dL 36
* Turbid samples are not suitable for Derived Fibrinogen determinations, as they may lead to abnormally low values. Interference of turbid
samples may occur even if triglyceride concentrations are within the normal range. Any questionable result should be followed up with a
more definitive quantitative method.
Limitations
Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no
interference was observed up to 6 g HES per liter plasma.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Thrombin Reagent on Sysmex® CA-500 System y = 1.00 x - 0.10 0.870
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (within-device CV) on the same lot of control plasma should be less than 10 %.
Measuring Range
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: g/L
Comments n Mean Median 2.5th - 97.5th Percentile
— 124 2.8 2.7 1.9 - 4.0
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 373
Hemoglobin mg/dL 1000
Bilirubin mg/dL 48
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Innovin® on Sysmex® CA-6000 System y = 1.03 x - 0.26 0.999
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.9 1.5 1.8
CONTROL N 0.4 0.2 0.4
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 2.5 - 97.5 Percentile
— 158 10.2 9.3 - 11.4
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 180 sec
Reag. Vol PT INN 100 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
Remarks
As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 373
Hemoglobin mg/dL 800
Bilirubin mg/dL 24
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Calibration with FNP pool and Dade® Innovin® on Sysmex® CA-500 series System y = 1.09 x - 0.57 1.000
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 2/ Dade® Ci-Trol® 2 1.9 2.0 2.7
CONTROL N 2.3 2.4 3.2
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: % of norm
th th
Comments n 2.5 - 97.5 Percentile
— 158 99 76 - 122
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
If the Derived Fibrinogen method is also used on the instrument, the Derived Fibrinogen method has to be disabled during the calibration
with PT-Multi Calibrator to avoid overwriting the Derived Fibrinogen master curve.
- Press [Standard Curve] - [Select Param.], disable the parameter No. 4 “dFbg”
- Perform calibration with PT-Multi Calibrator according to the Application Sheet
- Press [Standard Curve] - [Select Param.], enable the parameter No. 4 “dFbg”
Nevertheless, please check all calibration curve data afterwards.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Optional; only required to establish the MNPT.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 300
Hemoglobin mg/dL 1000
Bilirubin mg/dL 60
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Innovin® on Sysmex® CA-6000 System y = 1.08 x - 0.09 0.999
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.9 1.6 1.8
CONTROL N 0.4 0.2 0.4
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
System specific MNPT and ISI have to be used.
The Mean Normal PT (MNPT) can be established with Standard Human Plasma. To use Standard Human Plasma, it has to be measured at
least twice and the obtained clotting time has to be divided by the ratio given for the PT reagent in the lot-specific Table of Analytical Values
of the plasma.
ISI values for prothrombin time must be entered directly as they appear on the lot-specific table of ISI values. Any changes of the reagent lot,
software (upgrades), major service, etc., require verification of the ISI value. Failure to enter the correct ISI value will cause incorrect
International Normalization Ratio (INR) results.
As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 373
Hemoglobin mg/dL 1000
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Calibration with MNPT and ISI using Dade® Innovin® on Sysmex® CA-500 series System y = 1.07 x - 0.11 1.000
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.4 2.8 2.9
CONTROL N 1.0 1.1 1.5
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
If the Derived Fibrinogen method is also used on the instrument, the Derived Fibrinogen method has to be disabled during the calibration
with PT-Multi Calibrator to avoid overwriting the Derived Fibrinogen master curve.
- Press [Standard Curve] - [Select Param.], disable the parameter No. 4 “dFbg”
- Perform calibration with PT-Multi Calibrator according to the Application Sheet
- Press [Standard Curve] - [Select Param.], enable the parameter No. 4 “dFbg”
Nevertheless, please check all calibration curve data afterwards.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL ---*
Hemoglobin mg/dL 100
Bilirubin mg/dL 36
* Turbid samples are not suitable for Derived Fibrinogen determinations, as they may lead to abnormally low values. Interference of turbid
samples may occur even if triglyceride concentrations are within the normal range. Any questionable result should be followed up with a
more definitive quantitative method.
Limitations
Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no
interference was observed up to 3 g HES per liter plasma.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Thrombin Reagent on Sysmex® CA-500 System y = 1.25 x - 0.58 0.857
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (within-device CV) on the same lot of control plasma should be less than 10 %.
Measuring Range
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: g/L
Comments n Mean Median 2.5th - 97.5th Percentile
— 123 2.9 2.8 2.0 - 4.2
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
ACTIN B4218-1/-2
Reagent holder position 2 2/10 mL Reagent holder position 2 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
[2]
CaCl2 SOLUTION ORHO
Reagent holder position 7 15 mL Reagent holder position 7 [2]
CA CLEAN I Rinse position
964-0631-3
11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Actin® Reagent (cooled pos.) PTT ACT 48
® ®
Dade Actin Reagent (non-cooled pos.) 24
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 337
Hemoglobin mg/dL 40
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Actin® Activated Cephaloplastin Reagent on Sysmex® CA-6000 System y = 1.00 x - 0.20 0.982
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.6 1.3 1.4
CONTROL N 1.0 3.4 3.5
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 5 - 95 Percentile
— 111 25.7 25.6 21.4 - 30.6
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol PTT ACT 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 240 sec
Reag. Vol CaCl2 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
ACTIN FS ReagentB4218-20/-100
holder position 2 2/10 mL Reagent holder position 2 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
[2]
CaCl2 SOLUTION ORHO
Reagent holder position 7 15 mL Reagent holder position 7 [2]
CA CLEAN I Rinse position
964-0631-3
11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Actin® FS Reagent (cooled pos.) PTT FS 48
® ®
Dade Actin FS Reagent (non-cooled pos.) 24
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 331
Hemoglobin mg/dL 1000
Bilirubin mg/dL 6
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Actin® FS Activated PTT Reagent on Sysmex® CA-6000 System y = 1.00 x + 0.10 0.983
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.3 1.5 1.5
CONTROL N 0.5 0.2 0.5
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 5 - 95 Percentile
— 111 24.8 24.6 21.8 - 28.0
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol PTT FS 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 240 sec
Reag. Vol CaCl2 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
ACTIN FSL B4219
Reagent holder position 2 2/10 mL Reagent holder position 2 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
[2]
CaCl2 SOLUTION ORHO
Reagent holder position 7 15 mL Reagent holder position 7 [2]
CA CLEAN I Rinse position
964-0631-3
11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Actin® FSL Reagent (cooled pos.) PTT FSL 48
® ®
Dade Actin FSL Reagent (non-cooled pos.) 24
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 331
Hemoglobin mg/dL 200
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Dade® Actin® FSL Activated PTT Reagent on Sysmex® CA-6000 System y = 1.00 x + 0.10 0.990
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 3/ Dade® Ci-Trol® 3 0.4 1.4 1.5
CONTROL N 0.4 0.2 0.4
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 5 - 95 Percentile
— 111 27.9 27.7 24.5 - 32.8
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol PTT FSL 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 240 sec
Reag. Vol CaCl2 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
Remarks
As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.
According to Sysmex' troubleshooting instructions (CA series Measurement Evaluation and Check Methods), the Maximum Time can be
extended to 600 seconds, if an Analysis Time Over error still persists with the measurement.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Pathromtin SL OQGS
Reagent holder position 2 5 mL Reagent holder position 2 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Ci-Trol CONTROL 2 B4244-20 1 mL
Ci-Trol CONTROL 3 B4244-30 1 mL
Dade® Ci-Trol® 1 291070 1 mL
® ®
Dade Ci-Trol 2 291071 1 mL
Dade® Ci-Trol® 3 291072 1 mL
CONTROL N ORKE 1 mL
[2]
CaCl2 SOLUTION ORHO
Reagent holder position 7 15 mL Reagent holder position 7 [2]
CA CLEAN I Rinse position
964-0631-3
11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
The reagent must be gently inverted (5 to 8 times) to mix before first use.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
On-board Stability
Material Name in Test Protocol Time [h]
®
Pathromtin SL (cooled pos.) PTT PSL 48
Pathromtin® SL (non-cooled pos.) 24
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 378
Hemoglobin mg/dL 200
Bilirubin mg/dL 2.4
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Pathromtin® SL on Sysmex® CA-6000 System y = 0.99 x - 1.10 0.968
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 1/ Dade® Ci-Trol® 1 0.6 1.2 1.3
Ci-Trol CONTROL 2/ Dade® Ci-Trol® 2 0.9 2.4 2.5
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 5 - 95 Percentile
— 110 34.1 33.8 29.0 - 40.2
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 30 sec
Reag. Vol PTT PSL 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 150 sec
Reag. Vol CaCl2 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Multifibren U OWZG
Reagent holder position 3 2/5 mL Reagent holder position 3 [1]
FIBRINOGEN CALIBRATOR Sample rack OQVK
position 1 - 5 6 x 1 mL Sample rack position 1 - 5
Ci-Trol CONTROL 1 B4244-10 1 mL
Dade® Ci-Trol® 1 291070 1 mL
CONTROL N Any position ORKE
on sample rack 1 mL Any position on sample rack
CA CLEAN I Rinse position
964-0631-3
11 50 mL Rinse position 11
Additional Notes
The required controls and calibrators have to be transferred into appropriate sample cups.
CA CLEAN I has to be transferred into an appropriate vial.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
®
Multifibren U Fbg MFU 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 284
Hemoglobin mg/dL 800
Bilirubin mg/dL 36
Limitations
Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no
interference was observed up to 3 g HES per liter plasma.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Multifibren® U on BCT® System y = 1.01 x - 0.28 0.973
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 4.5 3.1 5.3
Pathological plasma pool 3.5 1.4 3.6
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: g/L
th th
Comments n Mean Median 5 - 95 Percentile
— 124 2.6 2.6 1.9 - 3.5
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Fibrinogen Calibrator 1 is not used in this test.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
FIBRINOGEN DETERMINATION — B4233-15SY Kit —
THROMBIN REAGENT Reagent holder—position 3 [1] 1 mL Reagent holder position 3 [1]
FIBRINOGEN STANDARD —
Sample rack position 1 1 mL Sample rack position 1
OV BUFFER (OVB) Buffer position —
12 15 mL Buffer position 12
THROMBIN REAGENT holder position 3 [1] 1/5 mL
Reagent B4233-25/-27 Reagent holder position 3 [1]
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Dade® Ci-Trol® 1 291070 1 mL
CONTROL P OUPZ 1 mL
Data-Fi FIBRINOGEN CONTROL B4233-22 1 mL
CA SYSTEM BUFFER (OVB) —[2] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
THROMBIN REAGENT Fbg 24
CA SYSTEM BUFFER (in GW5 or SLD vials) OVB 8
OV BUFFER (in GW5 or SLD vials) 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 341
Hemoglobin mg/dL 1000
Bilirubin mg/dL 48
Limitations
If samples are measured in a 1:5 dilution, any presence of elevated triglycerides or any other turbidity in the sample may interfere the
analysis.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
® ®
Dade Thrombin Reagent on Sysmex CA-1500 System y = 1.05 x + 0.04 0.974
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol CONTROL 1/ Dade® Ci-Trol® 1 1.9 4.1 4.6
Data-Fi FIBRINOGEN CONTROL 3.8 3.0 4.8
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: g/L
Comments n Mean Median 5th - 95th Percentile
— 123 2.73 2.70 2.10 - 3.58
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 5 µL
Dil.Vol OVB 95 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol Fbg 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
Sample Vol 20 µL
Dil.Vol OVB 80 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol Fbg 50 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
TEST THROMBIN — OWHM Kit —
REAGENT Reagent holder—position 2 [1] 5 mL Reagent holder position 2 [1]
REAGENT DILUENT — — 50 mL —
CONTROL N on sample rack 1 mL
Any position ORKE Any position on sample rack
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
Limitations
If the Thrombin Time is longer than the reference interval, determine the fibrinogen concentration. Report Thrombin Time if the fibrinogen
concentration is below or equal to 7 g/L. Do not report the Thrombin Time if the fibrinogen concentration is higher than 7 g/L.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT TestThr 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 341
Hemoglobin mg/dL 20
Bilirubin mg/dL 24
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Test Thrombin Reagent on BFA System y = 0.56 x + 5.69 0.946
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 6.2 3.9 7.0
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
Comments n Mean Median 2.5th - 97.5th Percentile
— 180 17.8 17.9 16.1 - 19.5
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol TestThr 100 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromboclotin 281007
Reagent holder position 2 10 mL Reagent holder position 2 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
® ®
Dade Ci-Trol 1 291070 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
Limitations
If the Thrombin Time is longer than the reference interval, determine the fibrinogen concentration. Report Thrombin Time if the fibrinogen
concentration is below or equal to 7 g/L. Do not report the Thrombin Time if the fibrinogen concentration is higher than 7 g/L.
On-board Stability
Material Name in Test Protocol Time [h]
Thromboclotin® Thrombo 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 284
Hemoglobin mg/dL 600
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 3.1 1.2 3.1
Pathological plasma pool 4.5 3.3 5.3
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
Refer to the Instructions for Use of the reagent.
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
Batroxobin REAGENT OUOV
Reagent holder position 4 5 mL Reagent holder position 4 [1]
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
® ®
Dade Ci-Trol 1 291070 1 mL
CONTROL N ORKE 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
Additional Notes
The required controls have to be transferred into appropriate sample cups.
CA CLEAN I has to be transferred into an appropriate vial.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
Batroxobin REAGENT Batrox 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 600
Hemoglobin mg/dL 1000
Bilirubin mg/dL 12
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Batroxobin Reagent on BCT® System y = 0.77 x + 5.66 0.984
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 1.0 1.2 1.5
Pathological plasma pool 1.9 0.7 1.9
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
th th
Comments n Mean Median 5 - 95 Percentile
— 66 17.6 17.6 16.7 - 18.9
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Sample Vol 50 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
2nd Dil
D.Samp Vol 0 µL
Dil.Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 1 60 sec
Reag. Vol Batrox 100 µL
Pre. Rinse ******* x0
Post. Rinse Clean I x1
Reagent 2 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
Reagent 3 0 sec
Reag. Vol ******* 0 µL
Pre. Rinse ******* x0
Post. Rinse ******* x0
[1]
The Management ID only applies to the CA-600 System.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Thromborel S OUHP
Reagent holder position 1 4/10 mL Reagent holder position 1 [1]
FACTOR VII DEFICIENT position 6 [2]
OTXV
Reagent holder 1 mL Reagent holder position 6 [2]
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CA SYSTEM BUFFER (OVB) —[3] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
Thromborel® S PT THS 24
FACTOR VII DEFICIENT VII 6
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 582
Hemoglobin mg/dL 1000
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Thromborel® S on BCT® System y = 1.04 x + 3.44 0.979
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 7.4 4.4 8.2
CONTROL P 4.1 7.7 8.6
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Coagulation Factors II, VII and X Deficient Plasma Instructions for Use.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® ®
Dade Innovin position 1 4/10/20 mL Reagent holder position 1 [1]
B4212
Reagent holder [1]
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
Dade® Innovin® PT INN 24
FACTOR VII DEFICIENT VII 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 3000
Hemoglobin mg/dL 1000
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Thromborel® S on BCT® System y = 0.97 x - 1.55 0.976
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 5.0 1.3 4.9
CONTROL P 3.9 1.8 4.1
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Coagulation Factors II, VII and X Deficient Plasma Instructions for Use.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
ACTIN B4218-1/-2
Reagent holder position 2 2/10 mL Reagent holder position 2 [1]
FACTOR VIII DEFICIENT OTXW
Reagent holder position 8 [2] 1 mL Reagent holder position 8 [2]
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CaCl2 SOLUTION ORHO
Reagent holder position 7 [2] 15 mL Reagent holder position 7 [2]
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 / 15 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
ACTIN PTT ACT 48
FACTOR VIII DEFICIENT VIII 4
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 453
Hemoglobin mg/dL 200
Bilirubin mg/dL 48
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Pathromtin® SL on BCT® System y = 1.05 x + 2.24 0.965
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 3.1 5.3 6.1
CONTROL P 4.6 6.2 7.6
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Coagulation Factors VIII, IX, XI and XII Deficient Plasma Instructions for Use.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
ACTIN FSL B4219
Reagent holder position 2 2/10 mL Reagent holder position 2 [1]
FACTOR VIII DEFICIENT OTXW
Reagent holder position 8 [2] 1 mL Reagent holder position 8 [2]
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CaCl2 SOLUTION ORHO
Reagent holder position 7 [2] 15 mL Reagent holder position 7 [2]
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
ACTIN FSL PTT FSL 48
FACTOR VIII DEFICIENT VIII 4
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 3000
Hemoglobin mg/dL 40
Bilirubin mg/dL 24
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Pathromtin® SL on BCT® System y = 1.00 x + 3.71 0.960
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 2.5 3.2 4.0
CONTROL P 3.2 4.2 5.2
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Coagulation Factors VIII, IX, XI and XII Deficient Plasma Instructions for Use.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
® [1]
Pathromtin SL OQGS
Reagent holder position 2 5 mL Reagent holder position 2 [1]
FACTOR VIII DEFICIENT OTXW
Reagent holder position 8 [2] 1 mL Reagent holder position 8 [2]
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CaCl2 SOLUTION ORHO
Reagent holder position 7 [2] 15 mL Reagent holder position 7 [2]
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
The reagent must be gently inverted (5 to 8 times) to mix before first use.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
Pathromtin® SL PTT PSL 48
FACTOR VIII DEFICIENT VIII 4
CaCl2 SOLUTION CaCl2 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 582
Hemoglobin mg/dL 1000
Bilirubin mg/dL 24
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Pathromtin® SL on BCT® System y = 1.19 x + 0.51 0.974
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 3.1 3.2 4.3
CONTROL P 3.1 2.6 3.9
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Coagulation Factors VIII, IX, XI and XII Deficient Plasma Instructions for Use.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
[1]
LA 1 REAGENT OQGP
Reagent holder position 1 2 mL Reagent holder position 1 [1]
LA 2 REAGENT OQGR
Reagent holder position 2 [1] 1 mL Reagent holder position 2 [1]
CONTROL N ORKE 1 mL Any position on sample rack
LA CONTROL 1 OQWE 1 mL
LA CONTROL 2 OQWD 1 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
Additional Notes
The required controls have to be transferred into appropriate sample cups.
CA CLEAN I has to be transferred into an appropriate vial.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
On-board Stability
Material Name in Test Protocol Time [h]
LA 1 REAGENT LA1 24
LA 2 REAGENT LA2 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 300
Hemoglobin mg/dL 100
Bilirubin mg/dL 60
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
LA 1 on BCT® System y = 1.26 x - 1.56 0.990
LA 1 / LA 2 Ratio on BCT® System y = 1.06 x + 0.03 0.993
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 5 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
LA 1: CONTROL N 0.8 2.0 2.2
LA 2: CONTROL N 0.5 0.8 1.0
LA 1 / LA 2 Ratio: CONTROL N 0.9 1.9 2.1
Measuring Range
Refer to the Instructions for Use of the analyzer for additional information.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: s
Comments n Mean Median 5th - 95th Percentile
LA 1 128 41.0 40.6 35.8 - 47.8
LA 2 128 36.1 36.0 33.3 - 39.3
LA 1 / LA 2 Ratio (no unit) 128 1.14 1.12 1.01 - 1.26
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
PROTEIN C COAG — OQYG Kit —
ACTIVATOR Reagent holder—position 1 [1] 3 mL Reagent holder position 1 [1]
REAGENT APTT Reagent holder—position 2 [1] 10 mL Reagent holder position 2 [1]
DEFICIENT Reagent holder—position 10 1 mL Reagent holder position 10
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CaCl2 SOLUTION ORHO
Reagent holder position 7 [2] 15 mL Reagent holder position 7 [2]
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
On-board Stability
Material Name in Test Protocol Time [h]
ACTIVATOR PC.A.cl 24
REAGENT APTT PC.APTT 24
DEFICIENT PC.DefP 6
CaCl2 SOLUTION CaCl2 24
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 3012
Hemoglobin mg/dL 600
Bilirubin mg/dL 36
Limitations
Hemolyzed samples are not suitable for protein C determination.
Higher levels of lipids or turbid samples can lead to falsely elevated or decreased values.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Protein C Reagent, coagulometric on BCT® System y = 1.01 x + 3.60 0.989
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 1.9 4.3 4.7
CONTROL P 2.5 4.5 5.1
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Instructions for Use of the reagent.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
®
INNOVANCE Antithrombin — OPFH Kit —
REAGENT Reagent holder—position 4 [1] 2.7 mL Reagent holder position 4 [1]
[2]
SUBSTRATE Reagent holder—position 6 2.7 mL Reagent holder position 6 [2]
BUFFER Reagent holder—position 10 5 mL Reagent holder position 10
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
Dade® Ci-Trol® 1 291070 1 mL
CONTROL N ORKE 1 mL
CONTROL P OUPZ 1 mL
CA SYSTEM BUFFER (OVB) —[3] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT ATReag 8
SUBSTRATE ATSub 8
BUFFER ATBuf 8
In order to achieve the maximum reagent stability over several days, we recommend the following procedure. Pour 0.9 mL INNOVANCE®
Antithrombin REAGENT, 0.9 mL INNOVANCE® Antithrombin SUBSTRATE, and 1.6 mL INNOVANCE® Antithrombin BUFFER from the
original vial into 3.5 mL sample cups, Catalog # 73-646. Place these cups on the system. Store the reagents in their closed original vials at
+2 °C to +8 °C. The same procedure can be followed again up to day 3. Under these conditions the stability data listed in the table above are
still valid. Please refer to the Instructions for Use “Once-opened stability” information regarding the stability for reagents stored in original
containers.
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 681
Hemoglobin mg/dL 1000
Bilirubin mg/dL 60
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
® ®
Berichrom Antithrombin III (A) on Sysmex CA-500 series System y = 0.98 x + 0.87 0.973
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (within-device CV) on the same lot of control plasma should be less than 10 %.
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: % of norm
Comments n Mean Median 2.5th - 97.5th Percentile
— 150 96.2 96.1 83 - 111
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Berichrom AT III — OWWR15 Kit —
REAGENT THR Reagent holder—position 4 [1] 5/15 mL Reagent holder position 4 [1]
SUBSTRATE Reagent holder—position 6 [2] 3 mL Reagent holder position 6 [2]
REAGENT THR DILUENT — — 30/100 mL —
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
Ci-Trol CONTROL 1 B4244-10 1 mL Any position on sample rack
® ®
Dade Ci-Trol 1 291070 1 mL
CONTROL N ORKE 1 mL
CONTROL P OUPZ 1 mL
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT THR AT3Thro 8
SUBSTRATE AT3Subs 8
CA SYSTEM BUFFER (in GW5 or SLD vials) OVB 8
OV BUFFER (in GW5 or SLD vials) 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 1200
Hemoglobin mg/dL 1000
Bilirubin mg/dL 60
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Berichrom® Antithrombin III (A) on Sysmex® CA-6000 System y = 0.95 x + 4.50 0.972
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 2.3 4.5 5.0
CONTROL P 2.9 9.5 9.9
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: % of norm
th th
Comments n Mean Median 2.5 - 97.5 Percentile
— 285 96.1 96.5 79.1 - 114.1
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Berichrom HEPARIN — OWLD Kit —
REAGENT AT Reagent holder—position 1 [1] 1 mL Reagent holder position 1 [1]
REAGENT FX Reagent holder—position 2 [1] 10 mL Reagent holder position 2 [1]
[1]
SUBSTRATE Reagent holder—position 3 2 mL Reagent holder position 3 [1]
REAGENT FX DILUENT — — 10 mL —
STANDARD PLASMA (SHP) Reagent holder position 9 or 101 mL
ORKL Reagent holder position 9 or 10
Ci-Trol HEPARIN CONTROL 1 B4224-50 1 mL Any position on sample rack
Ci-Trol HEPARIN CONTROL 2 B4224-60 1 mL
CONTROL N ORKE 1 mL
[2]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
For preparation of the Calibration Plasma (Standard Human Plasma with 1 U/mL Heparin) refer to the Instructions for Use. On-board
position: Sample rack position 1.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT AT AT3Reag 4
REAGENT FX FXaReag 4
SUBSTRATE HepSubs 4
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ... LMW heparin UF heparin
Triglycerides mg/dL 252 252
Hemoglobin mg/dL 100 400
Bilirubin mg/dL 36 60
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Berichrom® Heparin on BCT® System y = 0.92 x - 0.01 0.977
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Ci-Trol HEPARIN CONTROL 1 5.6 4.7 7.1
Ci-Trol HEPARIN CONTROL 2 4.0 5.2 6.4
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
For calibration purposes it is necessary to define Standard Human Plasma (SHP) as diluent in the test protocol. The diluent volume has to be
set to 0 µL.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Berichrom HEPARIN — OWLD Kit —
REAGENT AT Reagent holder—position 1 [1] 1 mL Reagent holder position 1 [1]
REAGENT FX Reagent holder—position 2 [1] 10 mL Reagent holder position 2 [1]
[1]
SUBSTRATE Reagent holder—position 3 2 mL Reagent holder position 3 [1]
REAGENT FX DILUENT — — 10 mL —
STANDARD PLASMA (SHP) Reagent holder position 9 or 101 mL
ORKL Reagent holder position 9 or 10
Berichrom HEPARIN LMW CALIBRATOR Sample rack OPCA
position 1 1 mL Sample rack position 1
Berichrom HEPARIN LMW CONTROL 1 OPCD 1 mL Any position on sample rack
Berichrom HEPARIN LMW CONTROL 2 OPCB 1 mL
CA SYSTEM BUFFER (OVB) —[2] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT AT AT3Reag 4
REAGENT FX FXaReag 4
SUBSTRATE HepSubs 4
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 252
Hemoglobin mg/dL 100
Bilirubin mg/dL 36
Performance Characteristics
Calibrator Comparison
The following study represents a functional correlation between standard curves of the 2nd WHO Standard for low molecular weight heparin
and the Berichrom® Heparin LMW Calibrator.
Predicate Device Regression Equation r
Berichrom® Heparin with WHO Standard y = 1.00 x + 0.04 0.998
r = Correlation Coefficient
Precision
The precision study was conducted using specimens collected in 3.2 % sodium citrate solution.
The standard deviation (SD) of the analytical system should be less than ± 0.05 IU/mL for a normal plasma and less than ± 0.15 IU/mL for a
sample of 1.0 IU/mL.
Mean Repeatability Within Device/Lab
(IU/mL) SD (IU/mL) SD (IU/mL)
Berichrom HEPARIN LMW CONTROL 1 0.38 ±0.01 ±0.02
Berichrom HEPARIN LMW CONTROL 2 0.81 ±0.02 ±0.02
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
For calibration purposes it is necessary to define Standard Human Plasma (SHP) as diluent in the test protocol. The diluent volume in the
test protocol has to be set to 0 µL. Define and set Standard Human Plasma on Reagent holder position 9 or 10. Set Berichrom® Heparin
LMW Calibrator on Sample rack postion 1.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Berichrom HEPARIN — OWLD Kit —
REAGENT AT Reagent holder—position 1 [1] 1 mL Reagent holder position 1 [1]
REAGENT FX Reagent holder—position 2 [1] 10 mL Reagent holder position 2 [1]
[1]
SUBSTRATE Reagent holder—position 3 2 mL Reagent holder position 3 [1]
REAGENT FX DILUENT — — 10 mL —
STANDARD PLASMA (SHP) Reagent holder position 9 or 101 mL
ORKL Reagent holder position 9 or 10
Berichrom HEPARIN UF CALIBRATOR Sample rack OPCC
position 1 1 mL Sample rack position 1
Berichrom HEPARIN UF CONTROL 1 OPBY 1 mL Any position on sample rack
Berichrom HEPARIN UF CONTROL 2 OPBZ 1 mL
CA SYSTEM BUFFER (OVB) —[2] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT AT AT3Reag 4
REAGENT FX FXaReag 4
SUBSTRATE HepSubs 4
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 252
Hemoglobin mg/dL 400
Bilirubin mg/dL 60
Performance Characteristics
Calibrator Comparison
The following study represents a functional correlation between standard curves of the 5th WHO Standard for unfractionated heparin and the
Berichrom® Heparin UF Calibrator.
Predicate Device Regression Equation r
Berichrom® Heparin with WHO Standard y = 0.96 x + 0.01 0.999
r = Correlation Coefficient
Precision
The precision study was conducted using specimens collected in 3.2 % sodium citrate solution.
The standard deviation (SD) of the analytical system should be less than ± 0.05 IU/mL for a normal plasma and less than ± 0.15 IU/mL for a
sample of 1.0 IU/mL.
Mean Repeatability Within Device/Lab
(IU/mL) SD (IU/mL) SD (IU/mL)
Berichrom HEPARIN UF CONTROL 1 0.27 ±0.01 ±0.01
Berichrom HEPARIN UF CONTROL 2 0.67 ±0.01 ±0.02
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Not applicable.
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
For calibration purposes it is necessary to define Standard Human Plasma (SHP) as diluent in the test protocol. The diluent volume in the
test protocol has to be set to 0 µL. Define and set Standard Human Plasma on Reagent holder position 9 or 10. Set Berichrom® Heparin UF
Calibrator on Sample rack postion 1.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Berichrom PROTEIN C — OUVV15 Kit —
ACTIVATOR Reagent holder—position 1 [1] 5/10 mL Reagent holder position 1 [1]
SUBSTRATE Reagent holder—position 2 [1] 3 mL Reagent holder position 2 [1]
ACTIVATOR DILUENT — — 30 mL —
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CA SYSTEM BUFFER (OVB) —[2] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
ACTIVATOR BCPCAct 48
SUBSTRATE BCPCSub 48
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 284
Hemoglobin mg/dL 400
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Berichrom® Protein C on BCT® System y = 1.05 x - 1.02 0.963
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 10 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N 1.6 1.0 1.8
CONTROL P 3.6 1.4 3.6
Measuring Range
The measuring range is defined by the concentration of the calibrators used.
Expected Values
Refer to the Instructions for Use of the reagent.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
D-Dimer PLUS — OQWW Kit —
D-Dimer PLUS REAGENT Reagent holder—position 8 [2] 3 / 4 mL Reagent holder position 8 [2]
D-Dimer PLUS ACTIVATOR Reagent holder—position 4 [1] 3 / 5 mL Reagent holder position 4 [1]
D-Dimer PLUS REAGENT DILUENT — — 25 mL —
D-Dimer PLUS STANDARD Sample rack OQXA
position 1 6 x 1 mL Sample rack position 1
D-Dimer CONTROL 1 Any position OQKA
on sample rack 1 mL Any position on sample rack
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I Rinse position 11
964-0631-3 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
It is recommended to place the original reagent vials on the system. If cups are used instead, do not leave the reagents on the system for
longer than described in the table of on-board stabilities and use Sample Cup Conical 4.0 mL, REF 424-1160-8.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
D-Dimer PLUS REAGENT DD.Pl.R 48
D-Dimer PLUS REAGENT (Conical Cup) 8
D-Dimer PLUS ACTIVATOR DD.Pl.A 48
D-Dimer PLUS ACTIVATOR (Conical Cup) 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL ---*
Hemoglobin mg/dL 400
Bilirubin mg/dL 60
* Turbid samples can lead to falsely elevated or decreased values even if triglyceride concentrations are within the normal range.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
D-Dimer PLUS on Sysmex® CA-7000 System y = 1.01 x + 16.92 0.992
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
D-Dimer CONTROL 1 2.4 1.8 2.9
Measuring Range
The D-Dimer PLUS total measuring range on the Sysmex® CA-500/CA-600 System extends from 47 µg/L to 9999 µg/L. This total measuring
range is achieved by a manually requested redilution of the sample if the range of the standard curve (approximately 47 µg/L - 2332 µg/L) is
exceeded.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: µg/L
th th
Comments n Mean Median 5 - 95 Percentile
— 130 152 115 < 50 - 372
24 samples were below the limit of detection of 50 µg/L.
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Both, DDPl and +DDP should be set in the test group setting to enable manual sample redilution if the standard curve range is exceeded.
All samples above the upper report limit should be repeated using the appropriate +DDP Setting again. The redilution has to be requested
manually.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
Advanced D-Dimer — OQWM Kit —
REAGENT Reagent holder—position 8 [2] 3 / 4 mL Reagent holder position 8 [2]
ACTIVATOR Reagent holder—position 4 [1] 3 / 5 mL Reagent holder position 4 [1]
REAGENT DILUENT — — 25 mL —
Advanced D-Dimer STANDARD Sample rackOQWR
position 1 6 x 1 mL Sample rack position 1
Advanced D-Dimer CONTROL 1 OQWT 1 mL Any position on sample rack
Advanced D-Dimer CONTROL 2 OQWV 1 mL
Advanced D-Dimer REAGENT DILUENT — OQWP 25 mL —
CA SYSTEM BUFFER (OVB) —[3] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I Rinse position 11
964-0631-3 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
It is generally recommended to place the reagents on the system using original vials. If cups are used instead, do not leave the reagents on
the system for longer than described in the table of On-board Stability and use Sample Cup Conical 4.0 mL, REF B4267-4.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT Ad.DD.R 48
REAGENT (Conical Cup) 8
ACTIVATOR Ad.DD.A 48
ACTIVATOR (Conical Cup) 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL ---*
Hemoglobin mg/dL 400
Bilirubin mg/dL 60
* Turbid samples can lead to falsely elevated or decreased values even if triglyceride concentrations are within the normal range.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
Advanced D-Dimer on Sysmex® CA-7000 System y = 1.01 x + 0.14 0.992
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
Advanced D-Dimer CONTROL 1 2.4 1.8 2.9
Advanced D-Dimer CONTROL 2 1.6 1.4 2.0
Measuring Range
The Advanced D-Dimer total measuring range on the Sysmex® CA-500/CA-600 System extends from 0.43 to 99.99 mg/L (FEU). This total
measuring range is achieved by a manually requested redilution of the sample if the range of the standard curve (approximately 0.43 - 17.00
mg/L(FEU)) is exceeded.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: mg/L (FEU)
th th
Comments n Mean Median 5 - 95 Percentile
— 130 1.29 0.98 < 0.43 - 3.17
24 samples were below the limit of detection of 0.43 mg/L (FEU).
Reference intervals may vary from laboratory to laboratory. Therefore, each laboratory should establish its own reference intervals.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Both, AdDD and +AdD should be set in the test group setting to enable manual sample redilution if the standard curve range is exceeded.
All samples above the upper report limit should be repeated using the appropriate +AdD setting again. The redilution has to be requested
manually.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
®
INNOVANCE D-Dimer — OPBP Kit —
REAGENT Reagent holder—position 6 [2] 4 mL Reagent holder position 6 [2]
[1]
BUFFER Reagent holder—position 4 5 mL Reagent holder position 4 [1]
SUPPLEMENT Reagent holder—position 8 [2] 2.6 mL Reagent holder position 8 [2]
DILUENT Reagent holder—position 10 5 mL Reagent holder position 10
CALIBRATOR Sample rack position
— 1 1 mL Sample rack position 1
INNOVANCE® D-Dimer CONTROLS — OPDY Kit —
CONTROL 1 — 1 mL Any position on sample rack
CONTROL 2 — 1 mL
INNOVANCE® D-Dimer DILUENT Reagent holder
OPBR
position 10 5 mL Reagent holder position 10
[3]
CA SYSTEM BUFFER (OVB) — — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I Rinse position 11
964-0631-3 50 mL Rinse position 11
Additional Notes
If reagents, rinse solutions or buffers are not supplied in vials, which fit on the instrument exactly it is necessary to transfer them into
appropiate vials.
The required controls and calibrators have to be transferred into 4 mL Conical Cups (catalog # 424-1160-8).
Push vials (Push Vial PV-10, catalog # 541-1352-1) and 5 mL vials from the BC Vial kit (catalog # OVKE) can be used as appropriate vials
for reagents, rinse solutions or buffers that are not supplied in vials that fit exactly on the instrument.
Plasma samples should not be stored frozen for more than 4 weeks. If frozen samples are stored longer than 4 weeks, they should be
measured in batch mode. Controls should be measured pre- and post-run.
[1]
Alternatively, any other cooled reagent position can be used.
Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.
[2]
Alternatively, any other non-cooled reagent position (positions 5 to 10) can be used.
[3]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT DDi.REA 16
REAGENT (Conical Cup) 4
DILUENT DDi.DIL 16
DILUENT (Conical Cup) 4
BUFFER DDi.BUF 16
BUFFER (Conical Cup) 4
SUPPLEMENT DDi.SUP 16
SUPPLEMENT (Conical Cup) 4
OV BUFFER (in GW5 or SLD vials) OVB 48
CA SYSTEM BUFFER (in GW5 or SLD vials) 48
In original vials, the reagents may be left on board the instrument continuously for 16 hours or stored on and off the instrument for intervals of
7 x 1 hour over a maximum period of 14 days.
Storage and stability are described in the Instructions for Use. INNOVANCE® D-Dimer controls need to validate each new test run.
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 400
Hemoglobin mg/dL 200
Bilirubin mg/dL 12
Limitations
Higher levels of lipids or turbid samples can lead to falsely elevated or decreased values. It is therefore recommended to perform an
additional centrifugation step of the plasma (10 minutes at approx. 15.000 x g) before analyzing lipemic patient specimens.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
INNOVANCE® D-Dimer on Sysmex® CA-1500 System y = 0.98 x + 0.03 0.998
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (within-device CV) on the same lot of control plasma should be less than 15 %.
Mean Repeatability Within-Device/Lab
(mg/L FEU) CV (%) CV (%)
INNOVANCE® D-Dimer CONTROL 1 0.30 5.3 6.7
INNOVANCE® D-Dimer CONTROL 2 2.69 3.9 5.2
Measuring Range
The INNOVANCE® D-Dimer total measuring range on the Sysmex® CA-500/CA-600 System extends from 0.19 to 35.20 mg/L FEU. This total
measuring range is achieved by a manually requested redilution of the sample if the redilution limits of 0.19 to 4.40 mg/L FEU are exceeded.
Samples with concentrations above 35.20 mg/L FEU can be further diluted manually with INNOVANCE® D-Dimer DILUENT.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: mg/L FEU
Comments n Mean Median 90th Percentile
— 150 --- --- 0.55
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
Both, DDi and +DDi should be set in the test group setting to enable manual sample redilution if the standard curve range is exceeded.
All samples above the upper report limit should be repeated using the appropriate +DDi setting again. The redilution has to be requested
manually.
The units of measure for INNOVANCE® D-Dimer assay are mg/L FEU. The software of the instruments uses only mg/L for technical reasons.
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
vWF Ag — OPAB Kit —
REAGENT (diluent added) Reagent holder—position 5 - 10
2 + 4 mL Reagent holder position 5 - 10
BUFFER (Glycine buffer) Reagent holder—position 5 - 10 5 mL Reagent holder position 5 - 10
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CA SYSTEM BUFFER (OVB) —[1] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
[1]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT vWFReag 8
BUFFER vWFBuf 8
CA SYSTEM BUFFER (OVB) OVB 8
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ...
Triglycerides mg/dL 300
Hemoglobin mg/dL 1000
Bilirubin mg/dL 36
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
vWF Ag on Sysmex® CA-1500 System y = 1.01 x + 1.33 0.995
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (total CV) on the same lot of control plasma should be less than 15 %.
Within Run Run to Run Total
CV (%) CV (%) CV (%)
CONTROL N (vWF) 1.3 1.1 1.6
CONTROL P (vWF) 1.7 1.9 2.5
Measuring Range
The vWF Ag total measuring range on the Sysmex® CA-500/CA-600 System extends from 6 % to 600 %. This total measuring range is
achieved by a manually requested redilution of the sample if the reportable range of the standard curve (12.5 % - 200 %) is fallen below or
exceeded.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: %
th th
Comments n Mean Median 5 - 95 Percentile
Total 204 105.3 99.1 61.7 - 178.1
Blood group 0 80 87.6 77.8 59.4 - 145.3
Other blood groups 124 116.7 114.2 70.6 - 183.7
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
In order to guarantee reliable analysis results it is crucial to modify the analysis parameter for this assay. The necessary technical
modification has to be done by a Siemens representative.
All samples with unknown vWF antigen concentration should be measured with vWF setting first.
vWF should also be set as +vWF and -vWF in the test group setting to enable manual sample redilution if the standard curve range is fallen
below or exceeded.
All samples above the upper report limit should be repeated using the appropriate +vWF setting. The redilution has to be requested
manually.
All samples below the lower report limit should be repeated using the appropriate -vWF setting. The redilution has to be requested manually.
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
The parameters defined in this application sheet have been developed by Siemens Healthcare Diagnostics to provide optimal product
performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other
assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact
on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation
and other findings.
The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations
are not validated or supported by Siemens.
Materials Required
Material REF Size On-board position
®
INNOVANCE VWF Ac — OPHL Kit —
REAGENT I Reagent holder—position 1 - 4 2.0 mL Reagent holder position 1 - 4
REAGENT II — 3.5 mL Reagent holder position 5 - 10
REAGENT III — 2.5 mL
STANDARD PLASMA (SHP) Sample rack ORKL
position 1 1 mL Sample rack position 1
CONTROL N ORKE 1 mL Any position on sample rack
CONTROL P OUPZ 1 mL
CA SYSTEM BUFFER (OVB) —[1] — Buffer position 12
OV BUFFER (OVB) B4234-25 15 mL
CA CLEAN I 964-0631-3
Rinse position 11 50 mL Rinse position 11
BC Vial Kit — OVKE 5 mL —
Additional Notes
If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropiate vials.
The required controls and calibrators have to be transferred into appropriate sample cups.
REAGENT I, II and III must not be used in Sysmex Sample Cups on the Reagent Holder Positions.
As a control in the low measurement range, Control Plasma P (OUPZ) diluted 1:3 with Dade® Owren’s Veronal Buffer or Dade® CA System
Buffer can be used. The assigned value is calculated by division of the concentration given in the Table of Assigned Values by the dilution
(divisor:3). The range of the diluted control is +/- 4.0 % of norm VWF.
[1]
For additional information please refer to the Appendix I.
On-board Stability
Material Name in Test Protocol Time [h]
REAGENT I WFAcI 8
REAGENT II WFAcII 8
REAGENT III WFAcIII 24
CONTROL N 4
CONTROL P 4
CONTROL P 1:3 diluted 4
REAGENT I and II may be stored on and off the instrument for intervals of 2 x 4 hours over a maximum period of 2 weeks. REAGENT III may
be stored on and off the instrument for intervals of 6 x 4 hours over a maximum period of 6 weeks.
The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental
conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.
Interference Studies
No interferences up to ... WFa/+WFa -WFa
Triglycerides mg/dL 416 ---*
Hemoglobin mg/dL 1000 200
Bilirubin mg/dL 60 48
* Turbid samples can lead to falsely elevated or decreased values even if triglyceride concentrations are within the normal range.
Performance Characteristics
The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.
Method Comparison
Predicate Device Regression Equation r
INNOVANCE® VWF Ac on BCS® / BCS® XP System y = 1.09x -0.98 0.994
r = Correlation Coefficient
Precision
The coefficient of variation of the analytical system (within-device CV) on the same lot of control plasma should be less than 15 %.
Mean Repeatability Within Device
(% of norm) CV (%) CV (%)
CONTROL N WFa 91.7 1.5 1.9
CONTROL P WFa 33.5 3.0 3.4
Pathological plasma pool 2 - WFa 8.9 3.4 4.5
Pathological plasma pool 3 +WFa 435 3.1 4.0
Measuring Range
The INNOVANCE® VWF Ac total measuring range on the Sysmex® CA-500/CA-600 System extends from 6 % to 500 %. This total
measuring range is achieved by a manually requested redilution of the sample as +WFa or -WFa if the reportable range of the standard is >
125 % or < 25 %.
Expected Values
In a study with ostensibly healthy subjects the following data were obtained:
Unit: % of norm
Comments n Mean Median 2.5th - 97.5th Percentile
Blood group independent 263 107.8 103.1 55.0 - 193.9
Blood group 0 129 92.5 89.3 50.6 - 147.4
Blood group non-0 134 122.6 120.0 72.7 - 208.2
Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each
laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.
For more information on establishing reference intervals see CLSI document C28-A3, “How to Define and Determine Reference Intervals in
the Clinical Laboratory; Approved Guideline.”
Bibliography Manufacturer
Refer to the Instructions for Use of the reagent. Siemens Healthcare Diagnostics Products GmbH
Emil-von-Behring-Str. 76
35041 Marburg / Germany
USA Distributor
Siemens Healthcare Diagnostics Inc.
Newark, DE 19714 USA
Remarks
All samples with unknown VWF activity concentration should be measured with WFa setting first.
Remarks
VWF should also be set as +WFa and -WFa in the test group setting to enable manual sample redilution if the standard curve range is fallen
below or exceeded.
All samples above the upper report limit should be repeated using the appropriate +WFa setting. The redilution has to be requested
manually.
All samples below the lower report limit should be repeated using the appropriate -WFa setting. The redilution has to be requested manually.
The errors listed in the table below may appear if the sample measured contains a very low or undetectable level of VWF (e.g. Type 3 von
Willebrand disease). If not already done, the sample should be measured by using the VWF low setting and also by using other assays, e.g.
VWF Ag.
Result Raw value Error code
*.**** *---.- Measurement Error
*.**** *---.- No Linearity
*.**** *---.- Reaction Curve Error
*.**** *---.- Range Over
*.**** *---.- Trans Light Low
Remarks
Important!
The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have
to be entered by the service only. Please contact your local service.
CA CLEAN II
CA CLEAN II is available as 45 mL, 500 mL and 5 L product variants (REF 10708787, 964-0611, 974-0581-0).
If required CA CLEAN II has to be transferred into an appropriate vial.
On-board Stability
The on-board stability of CA CLEAN I for all applications is 24 h (in PV-10 or SLD vials).
The on-board stability of CA CLEAN II is 24 h (in 4 mL conical cup).
®
Dade CA System Buffer
The REF for Dade® CA System Buffer is B4265. For positioning on the analyzer, the buffer has to be transferred into an appropriate vial.
Appendix II Page 1 of 2
Symbol names are depicted onto the reagent labels and are not translatable. In the following table symbol
names and corresponding product names in the language of this Reference Guide are listed.
Symbol name Product name
1. Reagents / Supplementary Reagents
® ®
ACTIN Dade Actin Activated Cephaloplastin Reagent
® ®
ACTIN FS Dade Actin FS Activated PTT Reagent
® ®
ACTIN FSL Dade Actin FSL Activated PTT Reagent
Batroxobin REAGENT Batroxobin Reagent
LA 1 REAGENT LA 1 Screening Reagent
LA 2 REAGENT LA 2 Confirmation Reagent
FACTOR VII DEFICIENT Coagulation Factor VII Deficient Plasma
FACTOR VIII DEFICIENT Coagulation Factor VIII Deficient Plasma
®
THROMBIN REAGENT Dade Thrombin Reagent
Advanced D-Dimer REAGENT DILUENT Advanced D-Dimer Reconstitution Medium
® ®
INNOVANCE D-Dimer DILUENT INNOVANCE D-Dimer Sample Diluent
CaCl2 SOLUTION Calcium Chloride Solution
CA CLEAN I CA CLEAN I
CA CLEAN II CA CLEAN II
®
CA SYSTEM BUFFER Dade CA System Buffer
®
OV BUFFER Dade Owren’s Veronal Buffer
Advanced D-Dimer Advanced D-Dimer
REAGENT Advanced D-Dimer Reagent
ACTIVATOR Advanced D-Dimer Activator
REAGENT DILUENT Advanced D-Dimer Reconstitution Medium
®
Berichrom AT III Berichrom Antithrombin III (A)
REAGENT THR Thrombin Reagent
SUBSTRATE Substrate Reagent
REAGENT THR DILUENT Buffer Solution
®
Berichrom HEPARIN Berichrom Heparin
REAGENT AT AT III Reagent
SUBSTRATE Substrate Reagent
REAGENT FX Factor Xa Reagent
REAGENT FX DILUENT Dextran Sulfate Reagent
®
Berichrom PROTEIN C Berichrom Protein C
ACTIVATOR Protein C Activator
SUBSTRATE Substrate Reagent
ACTIVATOR DILUENT Hepes Buffer Solution
D-Dimer PLUS D-Dimer PLUS
D-Dimer PLUS REAGENT D-Dimer PLUS Reagent
D-Dimer PLUS ACTIVATOR D-Dimer PLUS Accelerator
D-Dimer PLUS REAGENT DILUENT D-Dimer PLUS Reconstitution Medium
® ®
INNOVANCE Antithrombin INNOVANCE Antithrombin
®
REAGENT INNOVANCE Antithrombin Reagent
®
SUBSTRATE INNOVANCE Antithrombin Substrate
®
BUFFER INNOVANCE Antithrombin Buffer
® ®
INNOVANCE D-Dimer INNOVANCE D-Dimer
®
REAGENT INNOVANCE D-Dimer Reagent
®
BUFFER INNOVANCE D-Dimer Buffer
®
SUPPLEMENT INNOVANCE D-Dimer Supplement
®
DILUENT INNOVANCE D-Dimer Diluent
®
CALIBRATOR INNOVANCE D-Dimer Calibrator
Appendix II Page 2 of 2